Clinical Registry Unit (CRU)

The 1^st Medical department of the Johannes Gutenberg University Medical hospital is a department of internal medicine specializing in treatment of patients with hepatological diseases, gastrointestinal tumors especially primary liver cancer, endocrinology, rheumatology and nephrology.

History

Starting in 2003 we have established a clinical registry to document the clinical history of patients with hepatocellular carcinoma. The registry data enabled us to identify the liver function as a critical factor for the prognosis and the feasibility of sorafenib in treating HCC after recurrence following liver transplantation.

Building upon this foundation we extended the functionality to support liver disease, other tumor entities and rheumatological and kidney diseases.



Advantages of the CRU for the patient

•           Continuous reevaluation of therapy effectiveness and side effects to support shared decision making

• Identification of patients for clinicalal trials
• Continuous improvement of the clinical documentation
  

 Scientific benefits

• Availability of large clinically validated datasets for
  
  • long-term outcome research
  • generation of hypotheses
  • validation of basic science results
    

“Learning from clinical practice for better treatment decisions”

Team

Head

PD Dr. Arndt Weinmann, MBA
E-Mail: weinmann@mail.uni-mainz.de
Telephone: +49-6131-17-2666

Bioinformatics

Sandra Koch
E-Mail: sandra.koch@unimedizin-mainz.de
Telephone: +49-6131-17-

Cooperations

Data from the CRU has be used to externally validate clinical scores. If you are interested in a scientific cooperation using data of the CRU please contact Dr. Weinmann and we will check the feasibility of a cooperation.

Coordinators

Publications based on data of the CRU

• Grimm D, Lieb J, Weyer V, Vollmar J, Darstein F, Lautem A, Hoppe-Lotichius M, Koch S, Schad A, Schattenberg JM, Wörns MA, Weinmann A, Galle PR, Zimmermann T.
  Organic Cation Transporter 1 (OCT1) mRNA expression in hepatocellular carcinoma as a biomarker for sorafenib treatment.
  BMC Cancer. 2016 Feb 12;16(1):94.

• Berhane S, Toyoda H, Tada T, Kumada T, Kagebayashi C, Satomura S, Schweitzer N, Vogel A, Manns MP, Benckert J, Berg T, Ebker M, Best J, Dechêne A, Gerken G, Schlaak JF, Weinmann A, Wörns MA, Galle P, Yeo W, Mo F, Chan SL, Reeves H, Cox T, Johnson P.
  Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients.

  Clin Gastroenterol Hepatol. 2016 Jan 13. pii: S1542-3565(16)00044-6. doi: 10.1016/j.cgh.2015.12.042.

• Zöller D, Schmidtmann I, Weinmann A, Gerds TA, Binder H.
  Stagewise pseudo-value regression for time-varying effects on the cumulative incidence. Stat Med. 2015 Oct 28. doi: 10.1002/sim.6770.

• Kloeckner R, Weinmann A, Prinz F, Pinto dos Santos D, Ruckes C, Dueber C, Pitton MB.
  Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma. BMC Cancer 2015 Jun 10;15:465. doi: 10.1186/s12885-015-1480-x.
• Weinmann A, Alt Y, Koch S, Nelles C, Düber C, Lang H, Otto G, Zimmermann T, Marquardt JU, Galle PR, Wörns MA, Schattenberg JM.
  Treatment and survival of non-alcoholic steatohepatitis associated hepatocellular carcinoma. BMC Cancer. 2015 Apr 1;15:210. doi: 10.1186/s12885-015-1197-x.
• Sprinzl MF, Puschnik A, Schlitter AM, Schad A, Ackermann K, Esposito I, Lang H, Galle PR, Weinmann A, Heikenwälder M, Protzer U.
  Sorafenib inhibits macrophage-induced growth of hepatoma cells by interference with insulin-like growth factor-1 secretion.
  J Hepatol. 2015 Apr;62(4):863-70. doi: 10.1016/j.jhep.2014.11.011. Epub 2014 Nov 22.
• Pitton MB, Kloeckner R, Ruckes C, Wirth GM, Eichhorn W, Wörns MA, Weinmann A, Schreckenberger M, Galle PR, Otto G, Dueber C.
  Randomized comparison of selective internal radiotherapy (SIRT) versus drug-eluting bead transarterial chemoembolization (DEB-TACE) for the treatment of hepatocellular carcinoma.
  Cardiovasc Intervent Radiol. 2015 Apr;38(2):352-60. doi: 10.1007/s00270-014-1012-0. Epub 2014 Nov 7.
• Schmidtmann I, Elsäßer A, Weinmann A, Binder H.
  Coupled variable selection for regression modeling of complex treatment patterns in a clinical cancer registry.
  Stat Med. 2014 Dec 30;33(30):5358-70. doi: 10.1002/sim.6340. Epub 2014 Oct 27.
• Weinmann A, Koch S, Sprinzl M, Kloeckner R, Schulze-Bergkamen H, Düber C, Lang H, Otto G, Wörns MA, Galle PR.
  Survival analysis of proposed BCLC-B subgroups in hepatocellular carcinoma patients.
  Liver Int. 2015 Feb;35(2):591-600. doi: 10.1111/liv.12696. Epub 2014 Oct 31.
• Weinmann A, Sattler T, Unold HP, Grambihler A, Teufel A, Koch S, Schuchmann M, Biesterfeld S, Wörns MA, Galle PR, Schulze-Bergkamen H.
  Predictive scores in primary biliary cirrhosis: a retrospective single center analysis of 204 patients.
  J Clin Gastroenterol. 2015 May-Jun;49(5):438-47. doi: 10.1097/MCG.0000000000000176.
• Menke J, Amann K, Cavagna L, Blettner M, Weinmann A, Schwarting A, Kelley VR.
  Colony-stimulating factor-1: a potential biomarker for lupus nephritis.
  J Am Soc Nephrol. 2015 Feb;26(2):379-89. doi: 10.1681/ASN.2013121356. Epub 2014 Jul 10.
• Weinmann A, Koch S, Niederle IM, Schulze-Bergkamen H, König J, Hoppe-Lotichius M, Hansen T, Pitton MB, Düber C, Otto G, Schuchmann M, Galle PR, Wörns MA.
  Trends in epidemiology, treatment, and survival of hepatocellular carcinoma patients between 1998 and 2009: an analysis of 1066 cases of a German HCC Registry.
  J Clin Gastroenterol. 2014 Mar;48(3):279-89. doi: 10.1097/MCG.0b013e3182a8a793.
• Sprinzl MF, Reisinger F, Puschnik A, Ringelhan M, Ackermann K, Hartmann D, Schiemann M, Weinmann A, Galle PR, Schuchmann M, Friess H, Otto G, Heikenwalder M, Protzer U.
  Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells.
  Hepatology. 2013 Jun;57(6):2358-68. doi: 10.1002/hep.26328.
• Wörns MA, Koch S, Niederle IM, Marquardt JU, Nguyen-Tat M, Gamstätter T, Schuchmann M, Schulze-Bergkamen H, Galle PR, Weinmann A.
  The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib.
  Dig Liver Dis. 2013 May;45(5):408-13. doi: 10.1016/j.dld.2012.10.010. Epub 2012 Nov 21.
• Sprinzl MF, Weinmann A, Lohse N, Tönissen H, Koch S, Schattenberg J, Hoppe-Lotichius M, Zimmermann T, Galle PR, Hansen T, Otto G, Schuchmann M.
  Metabolic syndrome and its association with fatty liver disease after orthotopic liver transplantation.
  Transpl Int. 2013 Jan;26(1):67-74. doi: 10.1111/j.1432-2277.2012.01576.x. Epub 2012 Nov 5.
• Niederle IM, Wörns MA, Koch S, Nguyen-Tat M, Düber C, Otto G, Schuchmann M, Galle PR, Weinmann A.
  Clinicopathologic features and prognosis of young patients with hepatocellular carcinoma in a large German cohort.
  J Clin Gastroenterol. 2012 Oct;46(9):775-8. doi: 10.1097/MCG.0b013e31826102cc.
• Skowasch M, Schneider J, Otto G, Weinmann A, Woerns MA, Dueber C, Pitton MB.
  Midterm follow-up after DC-BEAD™-TACE of hepatocellular carcinoma (HCC).
  Eur J Radiol. 2012 Dec;81(12):3857-61. doi: 10.1016/j.ejrad.2012.07.002. Epub 2012 Jul 25.
• Wörns MA, Bosslet T, Victor A, Koch S, Hoppe-Lotichius M, Heise M, Hansen T, Pitton MB, Niederle IM, Schuchmann M, Weinmann A, Düber C, Galle PR, Otto G.
  Prognostic factors and outcomes of patients with hepatocellular carcinoma in non-cirrhotic liver.
  Scand J Gastroenterol. 2012 Jun;47(6):718-28. doi: 10.3109/00365521.2012.677952. Epub 2012 Apr 4.
• Weinmann A, Niederle IM, Koch S, Hoppe-Lotichius M, Heise M, Düber C, Schuchmann M, Otto G, Galle PR, Wörns MA.
  Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation.
  Dig Liver Dis. 2012 May;44(5):432-7. doi: 10.1016/j.dld.2011.12.009. Epub 2012 Jan 20.
• Gamstätter T, Weinmann A, Schadmand-Fischer S, Spies PR, Niederle IM, Schuchmann M, Galle PR, Wörns MA.
  AFP measurement in monitoring treatment response of advanced hepatocellular carcinoma to sorafenib: case report and review of the literature. Onkologie. 2011;34(10):538-42. Epub 2011 Sep 16.
• Wörns MA, Schuchmann M, Düber C, Otto G, Galle PR, Weinmann A.
  Sunitinib in patients with advanced hepatocellular carcinoma after progression under sorafenib treatment. Oncology. 2010;79(1-2):85-92. Epub 2010 Nov 12.
• Wörns MA, Weinmann A, Pfingst K, Schulte-Sasse C, Messow CM, Schulze-Bergkamen H, Teufel A, Schuchmann M, Kanzler S, Düber C, Otto G, Galle PR.
  Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
  J Clin Gastroenterol. 2009 May-Jun;43(5):489-95.